Sam Man Lee

Sam Man Lee
University of Illinois Chicago | UIC · Department of Endodontics

PhD in Medicine (Physiology)

About

12
Publications
2,661
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
147
Citations
Additional affiliations
July 2018 - present
Northwestern University
Position
  • PostDoc Position
February 2013 - November 2013
University of Adelaide
Position
  • Honours candidate
February 2014 - April 2018
University of Adelaide
Position
  • PhD Student
Description
  • Currently investigating the role of Toll-like receptor 4 (TLR4) in cardiac ischemic-preconditioning. Literature in the past two decades suggests that TLR4 bivalent signalling mechanism may exists and may be dependent on the level of TLR4 stimulation.

Publications

Publications (12)
Article
Peroxisome proliferator-activated receptor γ (PPARγ) belongs to a family of nuclear receptors that could serve as lipid sensors. PPARγ is the target of a group of insulin sensitizers called thiazolidinediones (TZD) which regulate the expression of genes involved in glucose and lipid metabolism, as well as adipokines that regulate metabolic function...
Article
Full-text available
Non-alcoholic steatohepatitis (NASH) is associated with obesity and increased expression of hepatic peroxisome proliferator-activated receptor γ (PPARγ). However, the relevance of hepatocyte PPARγ in NASH associated with obesity is still poorly understood. In this study, hepatocyte PPARγ was knocked out (PpargΔHep) in male and female mice after the...
Preprint
Full-text available
Background & Aims Non-alcoholic steatohepatitis (NASH) is associated with obesity and increased expression of hepatic peroxisome proliferator-activated receptor γ (PPARγ) in humans. Although we previously showed that the expression of PPARγ in hepatocytes contributes to the development NASH in lean mice, the relevance of hepatocyte PPARγ in the dev...
Article
Full-text available
Methods for the endogenous detection of nitroxyl (azanone; HNO), the reduced and protonated derivative of nitric oxide (NO), are required to define its cardiovascular function and its key role in chronic pain. This study reports the design, synthesis and biological evaluation of 3 super-bright, highly sensitive, specific and non-cytotoxic arylphosp...
Article
Thiazolidinediones (TZD) are peroxisome proliferator-activated receptor γ (PPARγ agonists that could reduce hepatic steatosis through their effects in adipose tissue, and therefore have been assessed as potential therapies to treat non-alcoholic fatty liver disease (NAFLD) in humans. However, some studies suggest that expression and activation of h...
Article
Full-text available
Background and aims Non-alcoholic steatohepatitis (NASH) is commonly observed in patients with type 2 diabetes, and thiazolidinediones (TZD) are considered a potential therapy for NASH. Although TZD increase insulin sensitivity and partially reduce steatosis and ALT, the efficacy of TZD on resolving liver pathology is limited. In fact, TZD may acti...
Conference Paper
Full-text available
Pparg is a nuclear receptor that regulates glucose and lipid metabolism. Thiazolidinediones (TZD) are PPARG agonists that may reduce hepatic steatosis through their effects in adipose tissue. However, some studies suggest that expression and activation of hepatocyte Pparg promotes steatosis. In this study, we have assessed the relevance of hepatocy...
Article
Background/objectives: Amitriptyline (AMY) is a tricyclic anti-depressant that has recently been shown to have anti-inflammatory properties. We investigated whether AMY is cardioprotective against reperfusion injury in ex-vivo rat hearts. Methods: Thirty adult Sprague-Dawley rat hearts were perfused ex-vivo in a Langendorff apparatus. All hearts...

Questions

Questions (5)
Question
I know that most people used HEPG2 or AML12 cells in liver studies but I'm curious why so few labs use FL83Bs (fyi: FL83B: ATCC® CRL-2390™).
Question
I'm currently studying the effects of glucagon in primary hepatocytes but I'm concerned that the media I am using (DMEM 10-1017 CV) is effecting my results. I suppose the real question is what is the most appropriate media that won't influence liver metabolism significantly. Has anyone used Williams E Medium or Ham's F-12K (Kaighn's) Medium? Ideally I want to replicate an environment where glucagon would be released (i.e. low glucose). Any advice would be appreciated.
Thanks,
Sam
Question
Hello everyone, 
I've been performing LAD ligations on Sprague Dawley rats but a large number of animals have died due to unknown reasons.Mortality only occurs once have finished the surgery and leave them on the ventilator until they recover. 
The only thing that appears to be abnormal are the rat's stomachs/ caecum which appear to look overinflated.  Post-mortem examination shows proper intubation and no visible signs of internal damage to the trachea.
What is also concerning is how quickly the animals die. Normally I would expect the animal to start experiencing arrythmias for several minutes however there have been instances in which the animal suddenly dies for no apparent reason. There have also been 1-2 incidents in which I have performed an sham but the animal suffers the same problem.
Any assistance would be greatly appreciated. 
Cheers,
Sam
Question
I was wondering whether anyone has worked with H9C2s and could recommend a cell lysis buffer or protocol. This cell-line is still new to me and I am currently optimizing a cell lysate protocol. My last troubleshooting run yielded very low protein concentrations and I'm not sure whether this is related to my protocol or the buffer used (which was RIPA buffer). Any advice would be greatly appreciated. 
Question
Hello everyone. I am interested in looking at hypoxia / reperfusion injury in H9c2 cells but there is one issue that is still bothering me. A majority of the papers I have looked at often use use hypoxia (or modular) incubator chambers to limit the amount of oxygen exposure. I was wondering whether it would be possible to use a normal incubator and fill it with 5% CO2 and 95% N2 to induce hypoxia. I'm also interested in stimulating ischemic-preconditoning but I'll need to figure out how to induce hypoxia properly first. Any advice or thoughts would be appreciated. 

Network

Cited By